As per the Global Burden of Disease (GBD) report, Chronic Obstructive Pulmonary Disease (COPD) has emerged as the second most significant contributor to death and disability-adjusted life years in ...
Our one-year fellowship is offered to PGY-4 level candidates for training focused on heart failure management, pulmonary HTN, with cardiology ICU exposure. Fellows develop the ability to recognize and ...
The FDA has granted a supplementary approval to Regeneron and Sanofi’s dupilumab (Dupixent) for use as an add-on therapy for inadequately controlled chronic obstructive pulmonary disease (COPD ...